U.S. Markets open in 8 hrs 14 mins

iShares Nasdaq Biotechnology ETF (IBB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
147.03-2.68 (-1.79%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close149.71
Open149.85
Bid0.00 x 1400
Ask0.00 x 800
Day's Range146.55 - 149.85
52 Week Range109.31 - 174.04
Volume3,409,022
Avg. Volume3,328,553
Net Assets10.74B
NAV150.02
PE Ratio (TTM)N/A
Yield0.20%
YTD Daily Total Return2.28%
Beta (5Y Monthly)0.91
Expense Ratio (net)0.46%
Inception Date2001-02-05
  • BlackRock Announces Product Updates to Two iShares ETFs
    Business Wire

    BlackRock Announces Product Updates to Two iShares ETFs

    BlackRock, Inc. (NYSE: BLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup.

  • Top Biotech Stocks for Q2 2021
    Investopedia

    Top Biotech Stocks for Q2 2021

    The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

  • CBD-focused Enveric Biosciences stock soars on heavy volume after license deal with cancer treatment company
    MarketWatch

    CBD-focused Enveric Biosciences stock soars on heavy volume after license deal with cancer treatment company

    Shares of Enveric Biosciences Inc. doubled in very heavy volume in midday trading Wednesday, after the Florida-based biotechnology company focused on cannabinoid-based treatments and cancer treatments said it acquired a perpetual license from Diverse Biotech for novel molecules for developing cancer treatments. Trading volume ballooned to 214.6 million shares, compared with the full-day average of about 2.4 million shares over the past 30 days. Enveric's stock, which was up 100%, was both the biggest gainer and most actively traded on major U.S. exchanges. "This is an exclusive, novel way of bringing together CBD and well-known, existing compounds that hold promise to create a new, improved drug class," added Enveric Chief Executive David Johnson. "As a patient-centric company, Enveric is constantly looking for new ways to eliminate or minimize cancer treatment side effects for patients in need." Enveric's stock has still lost 7.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 1.7% and the S&P 500 has gained 6.3%.